Quintrio
Home

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Instil Bio, Inc. Common Stock

TIL

Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.

Last trade $5.19
Day change -$0.56 (-9.74%)
Day range $5.18 – $5.77
Volume 109,010
Market cap $39M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$39M
Price / earnings
—
Price / book
0.36×
Price / sales
17.39×
EV / sales
52.92×
EV / EBITDA
-4.96×

Profitability

Earnings per share
-$3.26
Return on assets
-11.17%
Return on equity
-20.57%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.79×
Current ratio
21.67×
Quick ratio
21.67×
Cash ratio
1.68×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$23.61M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for TIL, quarterly periods
Line itemQ2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024Q3 FY2024 Sep 30, 2024
Revenue$0$0—$2.24M$0$0$2.77M$1.49M
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0—$2.24M$0$0$2.77M$1.49M
Selling, general and administrative$5.13M$5.35M—$5.9M$6.16M$9.11M$10.37M$10.71M
Research and development$270K$669K—$9.13M$16.74M$5.37M$1.1M$10.56M
Total operating expenses$5.58M$7.01M—$15.02M$23.44M$30.56M$11.82M$23.63M
Operating income-$5.58M-$7.01M—-$12.78M-$23.44M-$30.56M-$9.05M-$22.14M
Interest expense-$1.58M-$1.55M—-$1.58M-$1.58M-$1.1M-$3M-$2.01M
Income before taxes-$4.3M-$4.2M—-$13.59M-$21.39M-$28.2M-$11.9M-$23.02M
Income taxes$0$0—$0$0$0$0$0
Net income-$4.3M-$4.2M—-$13.59M-$21.39M-$28.2M-$11.9M-$23.02M
Net income attributable to common shareholders-$4.3M-$4.2M—-$13.59M-$21.39M-$28.2M-$11.9M-$23.02M
EBITDA-$5.15M-$6.01M$12K-$12.77M-$22.89M-$13.98M-$7.96M-$18.88M
Basic earnings per share-$0.63-$0.62—-$2.01-$3.24-$4.32-$1.82-$3.54
Diluted earnings per share-$0.63-$0.62—-$2.01-$3.24-$4.32-$1.82-$3.54

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Instil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update

Instil Bio (Nasdaq: TIL) reported Q1 2026 results with a cash position of $74.7 million, sufficient to fund operations beyond 2027. The company is actively evaluating acquisition and in-licensing opportunities to build its pipeline. R&D expenses decreased to $0.7 million from $5.4 million year-over-year, while net loss per share improved to $0.62 from $4.32.

GlobeNewswire Inc.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of First Solar, Inc. - FSLR

Pomerantz LLP is investigating potential securities fraud claims on behalf of investors in First Solar, Instil Bio, and Corcept Therapeutics. First Solar's stock fell 10.29% on January 7, 2026, following a Jefferies downgrade to Hold due to lowered guidance, significant de-bookings, margin compression, and limited deployment opportunities expected in 2026.

GlobeNewswire Inc.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. - ZBIO

Pomerantz LLP announced investigations into securities fraud claims on behalf of investors in three biotech companies. Zenas BioPharma's stock plummeted 51.86% following disappointing Phase 3 trial results for obexelimab, with the CEO acknowledging the drug's efficacy fell short of expectations, triggering an additional 8.49% decline. Similar investigations were initiated for Instil Bio and Corcept Therapeutics.

GlobeNewswire Inc.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AST SpaceMobile, Inc. - ASTS

Pomerantz LLP is investigating potential securities fraud claims on behalf of investors in AST SpaceMobile, Instil Bio, and Corcept Therapeutics. The investigation into AST was triggered by a Scotiabank downgrade to Sell on January 7, 2026, citing competition from SpaceX's Starlink, slow customer adoption, and satellite launch delays. AST's stock fell 12.06% following the downgrade.

The Motley Fool

Instil Bio Posts Wider Loss in Q2

Instil Bio reported a wider loss in Q2 2025, with Non-GAAP EPS of $(2.88), missing analyst expectations. The company increased R&D spending to $6.7 million and received FDA clearance for its lead drug candidate '2510, with plans to launch a U.S. clinical trial before year-end.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Dec 8, 20231-for-20reverse split